Gilead Sciences, Inc. (GILD) is a Drug Manufacturers - General company in the Healthcare sector, currently trading at $140.45. It has a SharesGrow Score of 78/100, indicating a strong investment profile with 6 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of GILD = $262.18 (+86.7% from the current price, the stock appears undervalued). Analyst consensus target is GILD = $159 (+13% upside).
Valuation: GILD trades at a trailing Price-to-Earnings (P/E) of 20.5 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 1.34.
Financials: revenue is $29.4B, +2.6%/yr average growth. Net income is $8.5B, growing at +534.9%/yr. Net profit margin is 28.9% (strong). Gross margin is 86.7% (+7.4 pp trend).
Balance sheet: total debt is $24.6B against $22.6B equity (Debt-to-Equity (D/E) ratio 1.09, moderate). Current ratio is 1.68 (strong liquidity). Debt-to-assets is 41.7%. Total assets: $59.0B.
Analyst outlook: 37 / 58 analysts rate GILD as buy (64%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 57/100 (Partial), Growth 73/100 (Pass), Past 100/100 (Pass), Health 83/100 (Pass), Moat 90/100 (Pass), Future 61/100 (Pass), Income 85/100 (Pass).
